Robert Rissman

Dr. Rissman is Professor Physiology and Neuroscience and the W.M. Keck Endowed Chair in Medicine at the University of Southern California (USC). He is the founding Director of the Neuroscience Translational Research Division (NTRD) at USC’s San Diego campus, Alzheimer’s Therapeutic Research Institute (ATRI). Concurrently with his research, Dr. Rissman also serves as the Biomarker Unit Lead for the Alzheimer’s Clinical Trials Consortium (ACTC) and USC’s Alzheimer’s Disease Research Center. The NTRD is comprised by a wet laboratory space and a large biorepository of -80 freezers to store specimens from clinical trials and longitudinal cohort studies. Using biobanked human specimens, animal and cell models, the goal of Dr. Rissman’s basic science research is to identify and validate plasma biomarkers for Alzheimer’s Disease and Related Disorders (ADRD) to better understand mechanisms of neurodegeneration and to streamline clinical trials recruitment. Work from Dr. Rissman’s lab has led to the validation of plasma biomarkers that predict AD brain neuropathology and progression of dementia and through analysis of plasma-derived extracellular vesicles, his group was also the first to demonstrate that TDP-43 protein within astrocyte extracellular vesicles can identify Limbic-predominant age-related TDP-43 encephalopathy (LATE). Using animal and cell culture models, Dr. Rissman’s lab is focused on understanding how synucleinopathy and other common comorbidities in AD can be identified and treated.

• Journal of Alzheimer’s Disease: Mark Smith Alzheimer’s Award, 2024

• University of California, San Diego, La Jolla, CA — BS — 06/1996
• Drexel University College of Medicine, Philadephia, PA — PhD — 12/2001
• University of California, Irvine, Irvine, CA — Postdoc — 01/2005
• Salk Institute for Biological Studies, La Jolla, CA — Staff Scientist — 09/2008

• Impact of Ethnicity on the Utility of Plasma Amyloid and Tau to Predict Alzheimer's Disease
  NIH · R01AG088623 · Sep 1, 2024 – May 31, 2029 · Role: Principal Investigator
• Impact of TBI and Cognitive Decline on Alzheimer's Disease Brain-Derived Exosome Cargo
  NIH · RF1AG079303 · Jun 1, 2023 – May 31, 2026 · Role: Principal Investigator
• The Health & Aging Brain Study – Health Disparities (HABS-HD)
  NIH · U19AG078109 · Sep 30, 2022 – Aug 31, 2027 · Role: Co-Principal Investigator
• Precision Medicine for Inflammatory Treatment for Alzheimer's Disease in Down Syndrome
  NIH · R01AG073979 · Sep 30, 2021 – Aug 31, 2026 · Role: Principal Investigator
• Novel Systemic Delivery of Peptide-Mediated Anti-Sense Oligonucleotides for Dementia with Lewy Bodies
  NIH · R01AG072053 · May 15, 2021 – Apr 30, 2026 · Role: Principal Investigator
• Novel Systemic Delivery of Peptide-Mediated Anti-Sense Oligonucleotides for Dementia with Lewy Bodies
  NIH · RF1AG072053 · May 15, 2021 – Apr 30, 2024 · Role: Principal Investigator
• Identifying Molecular Signatures associated with Alzheimer's Disease in the Retina
  NIH · R21AG070595 · Sep 11, 2020 – Aug 31, 2022 · Role: Principal Investigator
• Health and Aging Brain among Latino Elders (HABLE-AT(N)) Study
  NIH · R01AG058533 · Aug 1, 2020 – Apr 30, 2026 · Role: Co-Principal Investigator
• Novel Antagonists of the N-terminal Domain of the CRF Receptor Type 1 for Alzheimer's Disease
  NIH · RF1AG065385 · Jan 15, 2020 – Dec 31, 2023 · Role: Principal Investigator
• Neuronal exosomes to identify biomarkers and pathology of deployment-related TBI
  NIH · I01BX004312 · Oct 1, 2018 – Sep 30, 2022 · Role: Co-Principal Investigator
• Amyloid Burden among Mexican Americans
  NIH · R56AG058533 · Sep 30, 2018 – Jul 31, 2020 · Role: Co-Principal Investigator
• A Blood Test for Screening Into Alzheimer's Prevention Trials
  NIH · R01AG058252 · Sep 15, 2017 – Jun 30, 2022 · Role: Co-Principal Investigator
• Proteomic characterization of exosomes from AD patients
  NIH · R56AG057459 · Sep 15, 2017 – Aug 31, 2019 · Role: Co-Principal Investigator
• Biogenesis of Exosomes, Secretion, and Trafficking in Alzheimer's Disease
  NIH · R56AG057469 · Sep 15, 2017 – Aug 31, 2019 · Role: Principal Investigator
• A Proinflammatory Endophenotype to Predict NSAID Treatment Response Alzheimer's Disease Clinical Trials
  NIH · R01AG051848 · Sep 1, 2016 – Mar 31, 2021 · Role: Co-Principal Investigator
• Pathogenicity of neuronally-derived tau in exosomes
  NIH · R21AG051839 · Sep 1, 2016 – Apr 30, 2018 · Role: Principal Investigator
• Validation Studies of CRF Receptor 1 as a Target for AD
  NIH · I01BX003040 · Jul 1, 2016 – Jun 30, 2021 · Role: Principal Investigator
• Systems biology of HIV, methamphetamine and antiretrovirals interactions
  NIH · R01DA041750 · May 1, 2016 – Apr 30, 2021 · Role: Co-Principal Investigator
• Polytherapy for AD: Combining Gamma-secretase Modulation and CRFR1 Antagonism
  NIH · R21AG047484 · Sep 1, 2014 – Apr 30, 2016 · Role: Co-Principal Investigator
• Stress and CRF Signaling in Alzheimer?s Disease Pathogenesis
  NIH · R01AG032755 · Aug 15, 2008 – Jul 31, 2014 · Role: Co-Principal Investigator
• Role of Intracellular ABeta in Tau Pathology
  NIH · F32AG023433 · Jan 1, 2004 – Dec 31, 2004 · Role: Principal Investigator
• a-Synuclein vulnerability mechanisms and therapeutics in Alzheimer's Disease
  NIH · R01AG018440 · Sep 1, 2001 – May 31, 2022 · Role: Principal Investigator

• Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment. JAMA. 2026 Jul 14.. View in PubMed
• Relationships between longitudinal retinal amyloid imaging and amyloid PET in the A4 Trial. Alzheimers Dement (Amst). 2026 Jul-Sep; 18(3):e70422.. View in PubMed
• Neuropathological and functional impact of astrocyte-derived extracellular vesicles in an aged model of Alzheimer’s disease. Exp Neurol. 2026 Jul 03; 405:115893.. View in PubMed
• Impact of Repeated Antigen Exposure on Humoral Tolerance: Antidrug Antibodies After Single-Dose Versus Multi-dose Adalimumab. BioDrugs. 2026 Jul; 40(4):747-757.. View in PubMed
• Exploring automated plasma phospho-tau217 assays for the diagnosis of Down syndrome-related Alzheimer’s disease. Commun Med (Lond). 2026 Jun 02.. View in PubMed
• Retraction Note: Effects of innate immune receptor stimulation on extracellular α-synuclein uptake and degradation by brain resident cells. Exp Mol Med. 2026 Jun; 58(6):2036.. View in PubMed
• Sex-Dependent Effects of CSF1R-Mediated Myeloid Cell Depletion in a Mouse Model of Multiple System Atrophy. Eur J Neurosci. 2026 Jun; 63(12):e70586.. View in PubMed
• Neocortical tau burden determines the degree of cognitive impairment in individuals with Braak stage V neurofibrillary degeneration. Acta Neuropathol. 2026 May 25; 151(1).. View in PubMed
• Multimorbidity and Associations with Cognition and Alzheimer’s Disease Biomarkers. Ann Neurol. 2026 May 04.. View in PubMed
• Pre-analytical guidelines for blood and CSF Biomarkers 2025: Recommendations from the NACC ADRC Biofluid Biomarker Best Practices Workgroup. Alzheimers Dement. 2026 May; 22(5):e71252.. View in PubMed
• Differences in amyloid PET positivity based on ethnoracial group and social determinants of health: The new IDEAS study. Alzheimers Dement. 2026 May; 22(5):e71406.. View in PubMed
• Systemic delivery of anti-sense oligonucleotide targeting α-synuclein for treatment in a mouse model of multiple system atrophy. Front Aging Neurosci. 2026; 18:1807721.. View in PubMed
• Peptide-mediated delivery of an α-synuclein-targeting antisense oligonucleotide: Pharmacokinetics, safety, and central nervous system efficacy in a synucleinopathy model. Drug Metab Dispos. 2026 06; 54(6):100304.. View in PubMed
• Retraction Note: Effects of Novel Calpain Inhibitors in Transgenic Animal Model of Parkinson’s disease/dementia with Lewy bodies. Sci Rep. 2026 Apr 14; 16(1).. View in PubMed
• Continuum of Core 1 biomarkers in preclinical Alzheimer’s disease. Alzheimers Res Ther. 2026 Apr 10; 18(1).. View in PubMed
• Precision medicine for Alzheimer’s disease in Down syndrome. Alzheimers Dement. 2026 Apr; 22(4):e71398.. View in PubMed
• Sex Differences in P-Tau217, Tau Aggregation, and Cognitive Decline. JAMA Neurol. 2026 Apr 01; 83(4):369-381.. View in PubMed
• Retraction Note: Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy. Acta Neuropathol Commun. 2026 Mar 26; 14(1).. View in PubMed
• A repeat expansion in GOLGA8A is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions. Nat Genet. 2026 Apr; 58(4):726-736.. View in PubMed
• Structural signature of plasma proteins classifies the status of Alzheimer’s disease. Nat Aging. 2026 Mar; 6(3):597-611.. View in PubMed
• Correction: Selective targeting of 3 repeat Tau with brain penetrating single chain antibodies for the treatment of neurodegenerative disorders. Acta Neuropathol. 2026 Feb 19; 151(1):18.. View in PubMed
• Sex-dependent rescue of memory and synaptic deficits in AD model mice by increasing PSD-95 palmitoylation. Commun Biol. 2026 Feb 18; 9(1).. View in PubMed
• Analyses of astrocyte-neuron lactate shuttle transporter levels in brain tissues from people with HIV-associated neurocognitive impairment and Alzheimer’s disease. NeuroImmune Pharm Ther. 2026 Feb 16.. View in PubMed
• Relationships between fine memory discrimination and tau burden in two independent cohorts of older adults. Neuropsychologia. 2026 Apr 15; 224:109393.. View in PubMed
• The prognostic value of blood-based p-tau217 levels on progression to clinical impairment. medRxiv. 2026 Feb 09.. View in PubMed
• Whole blood gene expression moderates associations between AD biomarkers and cognitive decline in cognitively unimpaired older adults. Alzheimers Dement. 2026 Feb; 22(2):e71225.. View in PubMed
• Elevated temporal tau PET predicts faster cognitive decline in women than men: A meta-analysis. Alzheimers Dement. 2026 Feb; 22(2):e71031.. View in PubMed
• Retraction Note: Brain-derived exosomes from dementia with lewy bodies propagate α-synuclein pathology. Acta Neuropathol Commun. 2026 Jan 05; 14(1):3.. View in PubMed
• Blood gene expression network expression strongly relates to brain amyloid burden. Alzheimers Dement. 2025 12; 21(12):e70982.. View in PubMed
• Blood-based Transcriptomics Reveal Sex- and Amyloid-Modulated Biology of Plasma pTau217 in Preclinical Alzheimer’s Disease. bioRxiv. 2025 Nov 24.. View in PubMed
• Redirecting microglia phenotype via inhibition of NFAT1 ameliorates deficits in mouse model of synucleinopathies. Exp Mol Med. 2025 Nov; 57(11):2588-2607.. View in PubMed
• Systemic delivery of anti-sense oligonucleotide targeting a-synuclein for the treatment of multiple system atrophy. Res Sq. 2025 Nov 07.. View in PubMed
• The Neighborhoods Study: Examining the social exposome in Alzheimer’s disease and related dementias. Alzheimers Dement. 2025 11; 21(11):e70810.. View in PubMed
• Continuum of Core 1 Biomarkers in Preclinical Alzheimer’s Disease. medRxiv. 2025 Sep 19.. View in PubMed
• Transcriptome profiling of cerebrospinal fluid in Alzheimer’s disease reveals molecular dysregulations associated with disease. Alzheimers Dement (N Y). 2025 Jul-Sep; 11(3):e70152.. View in PubMed
• Racial and ethnic differences in plasma p-tau217 ratio biomarker eligibility rates in a preclinical AD trial with lecanemab. Alzheimers Dement (Amst). 2025 Jul-Sep; 17(3):e70164.. View in PubMed
• A brain-shuttled antibody targeting alpha synuclein aggregates for the treatment of synucleinopathies. NPJ Parkinsons Dis. 2025 Aug 22; 11(1):254.. View in PubMed
• Health and Aging Brain Study-Health Disparities (HABS-HD) methods and partner characteristics. Alzheimers Dement (N Y). 2025 Jul-Sep; 11(3):e70140.. View in PubMed
• Brain transcriptomics highlight abundant gene expression and splicing alterations in non-neuronal cells in aFTLD-U. Acta Neuropathol. 2025 Aug 10; 150(1):17.. View in PubMed
• Correction: Nicotine-mediated effects in neuronal and mouse models of synucleinopathy. Front Neurosci. 2025; 19:1662162.. View in PubMed
• Practice effects persist over two decades of cognitive testing: Implications for longitudinal research. medRxiv. 2025 Jul 31.. View in PubMed
• Neutral pH-Selective Inhibition of Cytosolic Cathepsin B: A Novel Drug Targeting Strategy for Traumatic Brain Injury and Alzheimer’s Disease. ACS Chem Biol. 2025 08 15; 20(8):1841-1848.. View in PubMed
• Methylome analysis of FTLD patients with TDP-43 pathology identifies epigenetic signatures specific to pathological subtypes. Mol Neurodegener. 2025 07 06; 20(1):80.. View in PubMed
• Amyloid PET and clinical management in a diverse, cognitively impaired population: The New IDEAS Study. Alzheimers Dement. 2025 07; 21(7):e70504.. View in PubMed
• A splice-switching antisense oligonucleotide targeting APP reduces accumulation of α-synuclein in a mouse model of Parkinson’s disease. Alzheimers Dement (N Y). 2025 Apr-Jun; 11(2):e70117.. View in PubMed
• Establishing tau-PET cut-points for cognitive diagnosis with 18 F-PI-2620 in a multi-ethnoracial cohort. Imaging Neurosci (Camb). 2025; 3.. View in PubMed
• Testing the causal impact of plasma amyloid on total Tau using a genetically informative sample of adult male twins. Aging Brain. 2025; 7:100139.. View in PubMed
• Differential roles of human tau isoforms in the modulation of inflammation and development of neuropathology. Neurobiol Dis. 2025 07; 211:106942.. View in PubMed
• Anti-Sense Oligonucleotide as a Therapeutic for Synucleinopathies: Pharmacokinetic, Safety and Efficacy Evaluation. bioRxiv. 2025 May 07.. View in PubMed
• Adverse Social Exposome During the Life Course and Vascular Brain Injury. JAMA Netw Open. 2025 05 01; 8(5):e2512289.. View in PubMed
• Antisense oligonucleotides directed against App and Rab5 normalized endosomal Rab activity and reversed DS-AD-linked degenerative phenotypes in the Dp16 mouse model of Down syndrome. Alzheimers Dement. 2025 05; 21(5):e70022.. View in PubMed
• Deciphering distinct genetic risk factors for FTLD-TDP pathological subtypes via whole-genome sequencing. Nat Commun. 2025 Apr 25; 16(1):3914.. View in PubMed
• WITHDRAWN: SARS-CoV-2 invades cognitive centers of the brain and induces Alzheimer’s-like neuropathology. bioRxiv. 2025 Apr 23.. View in PubMed
• Effects of exercise on cognition and Alzheimer’s biomarkers in a randomized controlled trial of adults with mild cognitive impairment: The EXERT study. Alzheimers Dement. 2025 04; 21(4):e14586.. View in PubMed
• Activation of Cytosolic Cathepsin B Activity in the Brain by Traumatic Brain Injury and Inhibition by the Neutral pH Selective Inhibitor Probe Z-Arg-Lys-AOMK. ACS Chem Neurosci. 2025 Apr 02; 16(7):1297-1308.. View in PubMed
• Pharmacokinetic and pharmacodynamic assessment of oral nicotinamide in the NEAT clinical trial for early Alzheimer’s disease. Alzheimers Res Ther. 2025 03 11; 17(1):59.. View in PubMed
• Characterization of plasma AT(N) biomarkers among a racial and ethnically diverse community-based cohort: an HABS-HD study. Alzheimers Dement (N Y). 2025 Jan-Mar; 11(1):e70045.. View in PubMed
• The Alzheimer’s Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study. Alzheimers Dement. 2025 02; 21(2):e14508.. View in PubMed
• Clinical and neuropathological analysis of Down syndrome over 7 decades of life. J Neuropathol Exp Neurol. 2025 Feb 01; 84(2):168-173.. View in PubMed
• Retraction Notice to “Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy” [Neurobiology of Disease 104 (2017) 85-96]. Neurobiol Dis. 2025 03; 206:106788.. View in PubMed
• Clinical criteria for limbic-predominant age-related TDP-43 encephalopathy. Alzheimers Dement. 2025 01; 21(1):e14202.. View in PubMed
• Guidelines for the standardization of pre-analytical variables for salivary biomarker studies in Alzheimer’s disease research: An updated review and consensus of the Salivary Biomarkers for Dementia Research Working Group. Alzheimers Dement. 2025 02; 21(2):e14420.. View in PubMed
• Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease. Neurology. 2025 Jan 14; 104(1):e210152.. View in PubMed
• Single step capture and assessment of multiple plasma extracellular vesicle biomarkers in Alzheimer’s disease detection. J Alzheimers Dis. 2024 Dec; 102(3):659-669.. View in PubMed
• A mutation in the PRKAR1B gene drives pathological mechanisms of neurodegeneration across species. Brain. 2024 Nov 04; 147(11):3890-3905.. View in PubMed
• AIBP controls TLR4 inflammarafts and mitochondrial dysfunction in a mouse model of Alzheimer’s disease. J Neuroinflammation. 2024 Sep 28; 21(1):245.. View in PubMed
• Learning precise segmentation of neurofibrillary tangles from rapid manual point annotations. bioRxiv. 2024 Sep 24.. View in PubMed
• Cannabis Use and Cannabidiol Modulate HIV-Induced Alterations in TREM2 Expression: Implications for Age-Related Neuropathogenesis. Viruses. 2024 09 24; 16(10).. View in PubMed
• Microglial and neuronal fates following inhibition of CSF-1R in synucleinopathy mouse model. Brain Behav Immun. 2025 Jan; 123:254-269.. View in PubMed
• Genome-wide association study meta-analysis of neurofilament light (NfL) levels in blood reveals novel loci related to neurodegeneration. Commun Biol. 2024 09 09; 7(1):1103.. View in PubMed
• Epigenetic and genetic risk of Alzheimer disease from autopsied brains in two ethnic groups. Acta Neuropathol. 2024 08 23; 148(1):27.. View in PubMed
• The Alzheimer’s Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau Round Robin study. medRxiv. 2024 Aug 22.. View in PubMed
• Testing the causal impact of amyloidosis on total Tau using a genetically informative sample of adult male twins. bioRxiv. 2024 Jul 26.. View in PubMed
• A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer’s Disease. Alzheimers Res Ther. 2024 07 05; 16(1):151.. View in PubMed
• Deciphering Distinct Genetic Risk Factors for FTLD-TDP Pathological Subtypes via Whole-Genome Sequencing. medRxiv. 2024 Jun 25.. View in PubMed
• Assessment of brain-derived extracellular vesicle enrichment for blood biomarker analysis in age-related neurodegenerative diseases: An international overview. Alzheimers Dement. 2024 07; 20(7):4411-4422.. View in PubMed
• The neuropathological landscape of small vessel disease and Lewy pathology in a cohort of Hispanic and non-Hispanic White decedents with Alzheimer disease. Acta Neuropathol Commun. 2024 05 24; 12(1):81.. View in PubMed
• Associations of plasma neurofilament light chain with cognition and neuroimaging measures in community-dwelling early old age men. Alzheimers Res Ther. 2024 04 25; 16(1):90.. View in PubMed
• Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer’s disease trial. Alzheimers Dement. 2024 06; 20(6):3827-3838.. View in PubMed
• Immunotherapy with an antibody against CD1d modulates neuroinflammation in an α-synuclein transgenic model of Lewy body like disease. J Neuroinflammation. 2024 Apr 15; 21(1):93.. View in PubMed
• From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer’s disease for targeted therapeutic approach. Alzheimers Dement (Amst). 2024 Apr-Jun; 16(2):e12580.. View in PubMed
• Amyloid precursor protein induces reactive astrogliosis. Acta Physiol (Oxf). 2024 06; 240(6):e14142.. View in PubMed
• AIBP controls TLR4 inflammarafts and mitochondrial dysfunction in a mouse model of Alzheimer’s disease. bioRxiv. 2024 Mar 27.. View in PubMed
• A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer’s Disease. medRxiv. 2024 Mar 22.. View in PubMed
• Midlife cumulative deficit frailty predicts Alzheimer’s disease-related plasma biomarkers in older adults. Age Ageing. 2024 03 01; 53(3).. View in PubMed
• Multi-omics Characterization of Epigenetic and Genetic Risk of Alzheimer Disease in Autopsied Brains from two Ethnic Groups. medRxiv. 2024 Feb 14.. View in PubMed
• CSF1R-mediated myeloid cell depletion shifts the ratio of motor cortical excitatory to inhibitory neurons in a multiple system atrophy model. Exp Neurol. 2024 Apr; 374:114706.. View in PubMed
• Correction: GP120 and tenofovir alafenamide alter cannabinoid receptor 1 expression in hippocampus of mice. J Neurovirol. 2024 Feb; 30(1):101-102.. View in PubMed
• Corrigendum to ” Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy Body Disease” [Neurobiology of Disease127 (2019) 163-177]. Neurobiol Dis. 2024 Feb; 191:106397.. View in PubMed
• Hippocampal ΔFosB expression is associated with cognitive impairment in a subgroup of patients with childhood epilepsies. Front Neurol. 2023; 14:1331194.. View in PubMed
• Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies. J Prev Alzheimers Dis. 2024; 11(4):802-813.. View in PubMed
• Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4. J Prev Alzheimers Dis. 2024; 11(4):831-837.. View in PubMed
• Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer’s Disease. J Prev Alzheimers Dis. 2024; 11(4):823-830.. View in PubMed
• Maximizing the Utility of Alzheimer’s Disease Trial Data: Sharing of Baseline A4 and LEARN Data. J Prev Alzheimers Dis. 2024; 11(4):889-894.. View in PubMed
• Characterization of Ptau181 Among a Diverse Community-Based Cohort: A HABS-HD Study. J Alzheimers Dis. 2024; 100(s1):S63-S73.. View in PubMed
• The AlzMatch Pilot Study – Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer’s Disease Trials. J Prev Alzheimers Dis. 2024; 11(5):1435-1444.. View in PubMed
• Amyloid precursor protein induces reactive astrogliosis. bioRxiv. 2023 Dec 18.. View in PubMed
• Emerging evidence for dysregulated proteome cargoes of tau-propagating extracellular vesicles driven by familial mutations of tau and presenilin. Extracell Vesicles Circ Nucl Acids. 2023; 4(4):588-598.. View in PubMed
• Association between military service and Alzheimer’s disease neuropathology at autopsy. Alzheimers Dement. 2024 02; 20(2):1468-1474.. View in PubMed
• Plasma Aβ42/Aβ40 and phospho-tau217 concentration ratios increase the accuracy of amyloid PET classification in preclinical Alzheimer’s disease. Alzheimers Dement. 2024 02; 20(2):1214-1224.. View in PubMed

• Aisen, Paul